The social phobia psychotherapy research network

Conditions

Social phobia (social anxiety disorder) Mental and Behavioural Disorders Social anxiety disorder

Altmann U, Gawlytta R, Hoyer J, Leichsenring F, Leibing E, Beutel M, Willutzki U, Herpertz S, Strauss B.

2020-02-225 citations

10.1016/j.janxdis.2020.102200

Changes of attachment characteristics during psychotherapy of patients with social anxiety disorder: Results from the SOPHO-Net trial

Bernhard Strauß, Uwe Altmann, Susanne Manes, Anne Tholl, Susan Koranyi et al. (20 authors)

PLoS ONE2018-03-0826 citations

10.1371/journal.pone.0192802

Do Patient Characteristics Predict Outcome of Psychodynamic Psychotherapy for Social Anxiety Disorder?

Jörg Wiltink, Jürgen Hoyer, Manfred E. Beutel, Christian Ruckes, Stephan Herpertz et al. (14 authors)

PLoS ONE2016-01-1927 citations

10.1371/journal.pone.0147165

Reliability, validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with social phobia.

Sonntag M, Konnopka A, Leichsenring F, Salzer S, Beutel ME, Herpertz S, Hiller W, Hoyer J, Joraschky P, Nolting B, Pöhlmann K, Stangier U, Strauss B, Willutzki U, Wiltink J, Leibing E, König HH.

2013-12-2319 citations

10.1186/1477-7525-11-215

Interventions

Manualized short-term psychodynamic psychotherapy (STPP) versus manualized cognitive-behavioral therapy (CBT)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of social phobia (SP) according to the Structured Interview for Diagnostic and Statistical Manual of Mental Disorders - fourth edition [SCID-I DSM-IV]) and primary diagnosis of social phobia according to the Liebowitz Social Anxiety Scale >302 2. Aged 18 to 59 versus 60 to 70 years 4. Participants must be made up of 60% women; 40% men

Exclusion criteria

Exclusion criteria: 1. Psychotic disorder 2. Risk of self-harm 3. Acute substance related disorder 4. Personality disorders except for cluster C 5. Organic mental disorder 6. Severe medical conditions 7. Concurrent psychotherapeutic or psychopharmacological treatment

Design outcomes

Primary

Measure	Time frame
For A1, primary outcome is no diagnosis of SP according to the SCID-I DSM-IV and the Liebowitz Social Anxiety Scale For C1, the primary outcome will be, that the psychotherapy outcome is associated with genetic variation in the serotonin transporter (SERT) gene (directed: L12 higher pre-post difference in the Liebowitz Social Anxiety Scale [LSAS]) For C2, primary outcomes will include normalisation of neural structural and functional abnormalities after successful treatment For C3, primary outcomes will be whether patients reveal a secure organized attachment; representation will reach a better outcome than those with insecure features and\or disorganized states of mind	—

Measure

Time frame

For A1, primary outcome is no diagnosis of SP according to the SCID-I DSM-IV and the Liebowitz Social Anxiety Scale For C1, the primary outcome will be, that the psychotherapy outcome is associated with genetic variation in the serotonin transporter (SERT) gene (directed: L12 higher pre-post difference in the Liebowitz Social Anxiety Scale [LSAS]) For C2, primary outcomes will include normalisation of neural structural and functional abnormalities after successful treatment For C3, primary outcomes will be whether patients reveal a secure organized attachment; representation will reach a better outcome than those with insecure features and\or disorganized states of mind

—

Secondary

Measure	Time frame
For A1, secondary outcomes will include: 1. Social anxiety (Social Phobia and Anxiety Inventory [SPAI]) 2. Depression (Beck Depression Inventory [BDI]) 3. Interpersonal problems (IIP) 4. Self-image 5. Quality of life or social functioning (short-form-12 questionnaire [SF-12]) 6. Costs and utilities of the treatments For C1, the secondary outcome will be, that the severity of social phobia is linked with genetic variation in SERT gene (directed: S10 higher LSAS at baseline) For C2 secondary outcome will include specificity of neural structural and functional abnormalities in social phobia For C3, secondary outcome will include whether a self-reported attachment will significantly change after successful therapy indicating increased security. This will be tested by using the Experiences in Close Relationships-Revised (ECR-R) instrument within the entire sample (n = 512)	—

Measure

Time frame

For A1, secondary outcomes will include: 1. Social anxiety (Social Phobia and Anxiety Inventory [SPAI]) 2. Depression (Beck Depression Inventory [BDI]) 3. Interpersonal problems (IIP) 4. Self-image 5. Quality of life or social functioning (short-form-12 questionnaire [SF-12]) 6. Costs and utilities of the treatments For C1, the secondary outcome will be, that the severity of social phobia is linked with genetic variation in SERT gene (directed: S10 higher LSAS at baseline) For C2 secondary outcome will include specificity of neural structural and functional abnormalities in social phobia For C3, secondary outcome will include whether a self-reported attachment will significantly change after successful therapy indicating increased security. This will be tested by using the Experiences in Close Relationships-Revised (ECR-R) instrument within the entire sample (n = 512)

—

Countries

Germany

Outcome results

None listed